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During a single bout of aerobic exercise, blood flow is shunted to exercising tissues 
while blood flow is maintained or reduced to less metabolically active areas (i.e. splanchnic 
area and non-working muscles).  Although increased sympathetic activation and multiple 
metabolic factors participate in redistributing blood flow during aerobic exercise, the precise 
mechanism is not entirely known.  The renin-angiotensin system (RAS), specifically the 
local vascular wall RAS, has been hypothesized to participate in the redistribution of blood 
flow during exercise. This study aimed to investigate whether vascular wall RAS in the 
femoral arteries (an artery which feeds active tissues during exercise) was altered by acute 
exercise, and if these vascular RAS alterations led to specific changes in vasomotor function.  
Male Sprague Dawley rats were exercised on a motorized treadmill for 1h at 21m/min with 
15% grade.  Immediately following exercise femoral arteries were excised, cleaned of 
surrounding connective tissue, and vascular RAS was evaluated.  There was a decrease in 
femoral ACE activity (~40%) and expression (~20%) following a single bout of exercise.  
No change was observed in AT1 and AT2 receptor expression.  To evaluate the effect of 
acute exercise and vascular RAS on vessel reactivity, vasomotor properties of the femoral 
arteries were assessed via vasoconstrictor and vasodilatory dose-response curves.  No 
changes were observed in femoral artery responses to potassium chloride (KCl), signifying 
that electromechanical coupling was not affected by exercise or RAS pharmacological 
interventions.  However, a significant decrease in maximum phenylephrine (PE) constriction 
was observed for acutely exercise animals (~13%).  Paired with the observed maintenance 
KCl-mediated constriction, it appears an acute bout of exercise is able to attenuate α-
adrenergic receptor-mediated vasoconstriction in the femoral artery.  The decrease in 
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maximum α-adrenergic vasoconstriction may be attributed to vascular RAS.  The decrease in 
ACE activity supports the production of local vasodilating factors.   Blocking AT1 receptors 
with telmisartan decreased PE constriction in control and exercised animals.  Combining AT1 
and AT2 receptor blockade (with PD123319) eliminated the attenuating effect of telmisartan 
alone on PE constriction.  This data suggests that the attenuating effect of AT1 receptor 
blockade, on PE constriction, may depend on AT2 receptor activation.  In addition, combined 
AT1 receptor blockade and nitric oxide synthase inhibition eliminated both the lone AT1 
receptor blockade effect and exercise effect on PE constriction.  Together, this data suggests 
that reduced PE constriction following acute exercise, and AT1 receptor blockade, is 
dependent on nitric oxide production.  Vasodilation to the nitric oxide donor sodium 
nitroprusside (SNP) was not altered following exercise or RAS pharmacological 
intervention, signifying no change in signaling downstream of NO production/release.  
Endothelium-dependent vasodilation to acetylcholine (ACh) was not affected by acute 
exercise.  However, responses to ACh were modulated by RAS pharmacological 
interventions supporting the responses seen in PE constriction and signifying the 

















Many people have helped me reach the completion of the following Master’s thesis 
and I would like to extend my deepest gratitude to them.  First, I would like to thank my 
advisor Dr. James W.E. Rush.  Thank you for giving me the opportunity to work within your 
lab and for guiding and supporting my ideas throughout this Masters degree.  This 
experience has strengthened me not only academically, but personally and I am truly 
thankful for your mentorship.  Best wishes to your growing family and I hope all the best for 
you in your future research endeavors.  Second, I would like to thank my committee 
members Dr. Joe Quadrilatero and Dr. Ken Stark for their valuable advice leading up to the 
completion of my Master’s degree.    Third, to my fellow lab-mates (in no particular order) 
Andrew Levy, Steve Denniss, Rebecca Ford, Jeff Kroetsch, Drew Graham, Kourtney Dupak, 
and Crystal Aultman, thank you for the all the help and support you have offered to me.  I 
cannot imagine a better group of people to work with, and I will always remember the laughs 
and good times we had in and out of the Rush Lab.  To the hooligans on the second floor of 
BMH – Michael Williams-Bell, Hamid Izadi, Payman Charkhzarin, Chris Vigna, Adam 
Metherel and Andrew Robertson, thanks for all the great times we had outside of academics 
playing intramural sports, golfing and partaking in other extracurricular activities.  To the 
hooligan not on the second floor of BMH – Roy So, thanks goes out to the best friend who 
provided motivation for my academic pursuits, while always having the time to participate in 
distractions away from academics.  To the Chung family, thanks for all your support 
throughout the years I’ve been in school (I still have some more), the phone calls and most 
importantly the tasty care-packages when I felt too lazy to cook. Last, but not least, a big 
thank you to Liana Yung.  I cannot thank you more for your constant love, kindness and 
vi 
 
encouragement in all aspects of my life; it truly cannot be explained in words.  Your 
enthusiasm for balance between work and personal life is inspiring and I’m glad you could 






































TABLE OF CONTENTS 
 
LIST OF TABLES………………………………………………………………………………ix 
 
LIST OF FIGURES……………………………………………………………………………..x 
 
LIST OF ABBREVIATIONS ………………………………………………………………….xii 
 
INTRODUCTION……………………………………………………………………………....1-16 
Renin Angiotensin System (Circulating vs. Local)……………………………………………...1 
Vascular Wall RAS………………………………………………………………………………….2 
RAS Pharmacology ………………………………………………………………………………...3 
AngII and Vascular NAD(P)H Oxidase………………………………………………………….5 
ROS production and agonist-induced vasoconstriction………………………………………..6 
Exercise acts as a stimulus for change in ROS production and vascular wall RAS……. ...9 







Plasma and Tissue ACE Activity………………………………………………………………….19 
Plasma AII levels……………………………………………………………………………………21 
Immunoblot Analyses……………………………………………………………………………….22 
Myography Protocol………………………………………………………………………………..23 
Identification of Femoral Artery Optimal Length………………………………………………23 
Assessment of electromechanical coupling and receptor-mediated vasoconstriction……..24 




Sprague Dawley Rat Characteristic and Exercise Protocol Confirmation...………………28 
Plasma ACE activity and AngII levels…………………………………………………………..28 
Femoral ACE activity……………………………………………………………………………...28 
Immunoblot Analyses………………………………………………………………………………29 
Assessment of electromechanical coupling……………………………………………………..29 
Assessment of α-adrenergic receptor-mediated vasoconstriction……………………………30 
Assessment of endothelium-dependent vasodilation …………………………………………..32 
Assessment of endothelium-independent vasodilation ………………………………………..34 
 
DISCUSSION…………………………………………………………………………………..70-81 
Acute exercise induced alterations in circulating RAS……………………….….…………….70 
Acute exercise induced alterations in femoral vascular wall RAS………………..………….71 
Acute exercise, femoral RAS and vasoconstriction…………………………….…….…………73 















































LIST OF TABLES 
 
Table 1: Sprague Dawley Rat Characteristics 
Table 2: Electromechanical coupling to potassium chloride (KCl) 
Table 3: Phenylephrine dose-response curve – p-values from two-way ANOVA 
Table 4: Phenylephrine dose-response curve – p-values from one-way ANOVA for MAX PE 
Table 5: Phenylephrine dose-response curve – p-values from one-way ANOVA for AUC 
Table 6: Phenylephrine dose-response curve characteristics for control animals 
Table 7: Phenylephrine dose-response curve characteristics for acute exercise animals 
Table 8: Endothelium-dependent relaxation to acetylcholine (ACh) 
Table 9: Acetylcholine dose-response curve characteristics for control animals 
























LIST OF FIGURES 
 
Figure 1: Circulating Renin-Angiotensin System 
 
Figure 2: Local Vascular Wall Renin-Angiotensin System 
 
Figure 3: Norepinephrine levels increase after acute exercise 
 
Figure 4: Epinephrine levels increase after acute exercise 
 
Figure 5: Plasma angiotensin II levels increase following acute exercise 
 
Figure 6: Plasma ACE activity is reduced following acute exercise 
 
Figure 7: Femoral ACE activity decreases following acute exercise 
 
Figure 8: Femoral ACE protein levels decrease following acute exercise 
 
Figure 9: Femoral AT1 protein levels are unchanged following acute exercise 
 
Figure 10: Femoral AT2 protein levels are unchanged following acute exercise 
 
Figure 11: No differences in CON and IPEx KCl dose-response curves 
 
Figure 12: Log EC50 values for L-NAME and TEL+L-NAME are different compared to all  
     other drug conditions 
 
Figure 13: Acute exercise effect on max α-adrenergic receptor-mediated constriction 
 
Figure 14: Effect of the AT1 receptor blocker telmisartan on max α-adrenergic receptor- 
     mediated constriction   
 
Figure 15: No effect of the ACE inhibitor captopril on max α-adrenergic receptor-mediated  
     constriction 
 
Figure 16: No effect of the AT2 receptor blocker PD123319 on max α-adrenergic receptor- 
     mediated constriction 
 
Figure 17: The effect of combined ACE inhibitor and AT1 receptor blocker on max α- 
     adrenergic receptor-mediated constriction 
 
Figure 18: The effect of combined AT1 and AT2 receptor blockade on max α-adrenergic  
     receptor-mediated constriction 
 
Figure 19: The effect of nitric oxide synthase (NOS) inhibition on max α-adrenergic receptor- 





Figure 20: Effect of Combined AT1 blockade and nitric oxide synthase (NOS) inhibition on  
      max α-adrenergic receptor-mediated constriction 
 
Figure 21: No exercise effect observed in max endothelium-dependent vasodilation to  
     acetylcholine 
 
Figure 22: Increased max endothelium-dependent vasodilation to acetylcholine with AT1  
     receptor blockade 
 
Figure 23: No effect of ACE inhibition on max endothelium-dependent vasodilation to  
     acetylcholine 
 
Figure 24: Effect of AT2 receptor blockade on endothelium-dependent vasodilation to  
      Acetylcholine 
 
Figure 25: Effect of combined ACE inhibition and AT1 receptor blockade on max  
     endothelium-dependent vasodilation to acetylcholine 
 
Figure 26: Effect of combined AT1 and AT2 receptor blockade on max endothelium-dependent  
      vasodilation to acetylcholine 
 
Figure 27: The effect of nitric oxide synthase (NOS) inhibition on max endothelium- 
     dependent vasodilation.   
 
Figure 28: Effect of Combined AT1 blockade and nitric oxide synthase (NOS) inhibition on  
     max endothelium-dependent vasodilation 
 
Figure 29: No changes in endothelium-independent vasodilation across exercise and drug  



















LIST OF ABBREVIATIONS 
 
ACE Angiotensin Converting Enzyme 
ACh Acetylcholine 
AngI Angiotensin I 
AngII Angiotensin II 
ARBs Angiotensin receptor blockers 
ATR Angiotensin Receptors 
AUC area under curve 
AVP arginine vasopressin 
B2 bradykinin receptor 2 





EC50 half maximal effective concentration 
eNOS endothelial nitric oxide synthase 
HHL L-Hip-His-Leu 
HL L-histidyl-L-leucine 
HRP horseradish peroxidase 
IP3 Inositol 1,3,5-triphosphate 
IPEx Immediate post-exercise 
KCl potassium chloride 
LIMA 
 
left internal mammry artery 
L-NAME ωN-nitro-L-arginine methyl ester  
MAX maximum 
NAD(P)H nicotinamide adenine dinucleotide phosphate 
ND No drug 
NE Norepinephrine 
NO nitric oxide 
NOS nitric oxide synthase 
PD PD123319 
PE Phenylephrine 
PKC protein kinase C 
PPARγ peroxisome proliferator activated receptor 
PWV pulse-wave velocity 
RAS Renin-Angiotensin System 
ROS rective oxygen species 
SD Sprague Dawley Rat 
xiii 
 
SDS sodium dodecyl sulphate 
SHR Spontaneously hypertensive rat 
SNP sodium nitroprusside 
SOD superoxide dismutase 
TBS-T tris buffered saline with Tween 20 
TEL telmisartan 
TPR total peripheral resistance 
















Renin Angiotensin System (Circulating vs. Local) 
It is well known that the renin-angiotensin system (RAS) participates in blood 
pressure regulation and fluid homeostasis [1].  A series of events occurs in the circulation to 
produce the effector peptide of RAS, Angiotensin II (AngII).  A decrease in arterial blood 
pressure stimulates renin release from the kidney.  Renin acts on its circulating substrate, 
hepatic-derived angiotensinogen, to form the decapeptide angiotensin I (AngI).  AngI is then 
converted to the active octapeptide AngII by a zinc-containing metalloprotein, angiotensin 
converting enzyme (ACE).  AngII can then normalize blood pressure by increasing total 
peripheral resistance, while also inhibiting water and sodium excretion for long-term 
stabilization of blood pressure (See Figure 1) [1].  Recent evidence, however, indicates that 
the traditional view of the RAS as a circulating endocrine system may be an over-
simplification.  Many tissues (such as blood vessels, brain, and kidney) express renin, 
angiotensinogen and ACE [2].  Furthermore, in-vitro cell culture work and in-vivo animal 
studies have identified local tissue production of AngI, AngII and AngII metabolites [1-4].  
Thus, expanding our appreciation of local tissue RAS systems will be necessary to fully 
comprehend pathology associated with RAS. 
Local RAS contributes to AngII production within tissues, eliciting physiological 
responses independent of circulating systemic AngII (i.e. paracrine function) [5].  In fact, 
AngII synthesis by local RAS can be further categorized as either extrinsic or intrinsic 
production.  Extrinsic formation of AngII occurs primarily at the surface of the blood vessels.  
ACE, present on the luminal face of vascular endothelial cells, actively converts AngI to 
AngII, which is either circulated throughout the body for systemic action or sequestered into 
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the vascular tissue for local action [2].  The basis of intrinsic local RAS relies on the 
existence of functional RAS components within tissue cells, which produce AngII for local 
action only [2].  Danser et al. quantified  local vascular wall RAS and reported that a 
substantial fraction of AngII being produced and sequestered did not occur in the plasma as it 
passed through the vascular bed [6;7].    The extrinsically and intrinsically generated AngII 
influences local cellular and molecular function and structure via interaction with angiotensin 
receptors (ATR) [2;3;8].  Although most known physiological and pathophysiological effects 
are mediated through AT1 receptor isoform, evidence suggests that some local action is 
mediated through the AT2 isoform.    
 
Vascular Wall RAS 
Despite debate over whether renin is expressed within the vasculature, ACE mRNA 
and protein have been readily found in the endothelium and adventitia (See Figure 2) [9-11].  
Furthermore, isolated hindlimb preparations have shown ~50% conversion of AngI to AngII 
after a single pass through the vessel bed [12] suggesting a robust local vascular ACE 
capacity.  The AngII production in the hindlimb preparations was abolished by the ACE 
inhibitor captopril, identifying the functional role of vascular wall RAS in AngII production.  
ATRs have also been identified in endothelial and vascular smooth muscle cells (VSMC), 
where locally produced AngII may bind [13].    Thus, growing evidence suggests localization 
and functionality of RAS components within the blood vessel wall. 
Although the blood vessel wall is an effector organ for circulating RAS (AT1 
receptors localized on VSMC mediate vasoconstriction), locally produced AngII can affect 
various properties of vascular cells.  Classically, AT1 receptors were thought to only mediate 
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vasoconstriction, in response to systemic or local AngII, through a phospholipase C-
dependent mechanism [14-16].  Inositol 1,4,5-trisphosphate (IP3) signaling leads to an 
increase in myoplasmic calcium and diacylglycerol (DAG) signaling activates protein kinase 
C (PKC), both triggering VSMC contraction.  However, AT1 receptor activation has also 
been implicated in other cellular events such as: smooth muscle proliferation[17], 
extracellular matrix formation[18], angiogenesis[19], activation and upregulation of 
nicotinamide adenine dinucleotide phosphate (NAD(P)H) oxidase[20].  The ability of AngII 
to alter vascular wall growth properties, and function, has motivated cardiovascular disease 
research to uncover therapeutic interventions involving local vascular wall RAS. 
 
RAS Pharmacology  
Several lines of experimental and clinical evidence have documented that disorders of 
the RAS play a central role in the development and progression of hypertension, as well as 
many other cardiovascular diseases such as myocardial infarction, stroke, and congestive 
heart failure[21].  Thus, pharmacological interventions, designed to interfere with RAS, have 
become widely used for the management of hypertension and other cardiovascular diseases.  
The earliest drug intervention developed to interfere with RAS aimed to block the enzymatic 
activity of ACE.  Cushman and Ondetti developed the first ACE inhibitor [22] based on 
purified peptides from the venom of the Brazilian pit viper (Bothrops jararaca).  A specific 
sequence of nine peptides from the viper venom, termed teprotide, was shown to lower blood 
pressure in humans; especially those with high circulating levels of renin[22].  However, the 
use of the teprotide was limited due to its peptide nature – the nonapeptide had a short 
biological half-life and required intravenous administration[23].  A breakthrough in ACE 
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inhibitor development came in 1976 when Cushman, Ondetti and Rubin designed the orally 
active ACE inhibitor, captopril, using a hypothetical model of the ACE active site, based on 
carboxypeptidase A (another zinc containing metalloprotein)[23].  Captopril had a high level 
of oral bioavailability and was effective in lowering blood pressure in renin-dependent 
experimental models of hypertension[22].   In 1981, the United States Food and Drug 
Administration approved the use of captopril[23].  Several ACE inhibitors have been 
developed since 1981 and ACE inhibitors continue to be widely used solely or in 
combination with other RAS blockers to treat hypertension and various cardiovascular 
diseases.   
 For many hypertensive patients angiotensin receptor blockers (ARBs), specifically the 
sartan class of drugs that selectively block the AT1 receptor subtype [24], are commonly 
prescribed in combination ACE inhibitors in pharmacological treatment regiments.  ARBs 
were developed to completely block the physiological actions of AII via competition at the 
receptor level.  ARBs, in combination with ACE inhibitors, are required for increased 
interference of RAS since it is known that a significant proportion (up to 40%) of AngII is 
formed through non-ACE dependent pathways;  angiotensinogen is converted to AngII via 
the enzymes cathepsin G, elastase, and tissue plasminogen activator, or from AngI to AngII 
by enzymes including chymase[24].  In addition, studies have cited limited tissue penetration 
of ACE inhibitors, which contributes to persistent AngII formation during ACE inhibitor 
therapy[25]; indicating a distinct therapeutic role for ARBs in combination with ACE 
inhibitors.  A specific ARB, telmisartan, has gained popularity recently due to its strong 
binding affinity, a reported long term effect over a 24hr period, and for its prospective use in 
the management of metabolic syndrome.  Large scale clinical studies on telmisartan have 
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reported substantial antihypertensive effects (reduction of blood pressure values throughout 
the 24hr average interval) of the drug within 1-2 weeks of initiating therapy[21].     
Interestingly, the antihypertensive effect follows the circadian rhythm of patients (measured 
via ambulatory BP monitoring), allowing protection of the cardiovascular system against the 
early morning BP rise and its adverse effects on the heart and vital organs[26].   Telmisartan 
is also capable of activating peroxisome proliferator activated receptor γ (PPARγ), which 
may be important in the prevention or treatment of metabolic syndrome (a cluster of 
metabolic and cardiovascular risk factors that predispose to heart attack, stroke, heart failure 
and sudden cardiac death)[27].  PPARγ activation is known to increase energy expenditure, 
improved lipid profile[28], increased insulin sensitivity [29], blood pressure reduction[27], 
and amelioration of the associated pro-inflammatory and pro-atherogenic risk profiles[30].  
Therefore, telmisartan may not only be an important drug intervention in the treatment of 
hypertension, but may also prove to be useful in a variety of cardiovascular complications 
through its ability to integrate and modulate two major metabolic pathways – one through 
activation of PPARγ pathway, and the second by selectively blocking the AT1-dependent 
pro-inflammatory, pro-atherogenic pathway without opposing the AT2-dependent anti-
inflammatory pathway. 
 
AngII and Vascular NAD(P)H Oxidase 
All vascular cell types including endothelial cells, smooth muscle cells, adventitial 
fibroblasts, and resident macrophages produce reactive oxygen species (ROS) [31-33].  ROS 
is of particular physiological importance since it acts as an inter- and intra-cellular signaling 
molecule.  Under pathological conditions, however, an increased generation of ROS 
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occurs[34].  An increased ROS load alters nitric oxide (NO) bioavailability and redox-
sensitive signaling pathways, leading to cellular processes involved in structural remodeling 
of blood vessels and vascular dysfunction[32].  A major free radical involved in the 
pathology of vascular dysfunction is superoxide anion[32].  Superoxide anion has an 
unpaired outer shell electron, which makes the molecule highly reactive, but also unstable 
and short-lived.  It is water soluble and can cross cell membranes through anion 
channels[35].  The major source of superoxide anion in the vascular wall is non-phagocytic 
NAD(P)H oxidase in endothelial cells and VSMC [36].  Vascular NAD(P)H oxidase is a 
multisubunit enzyme comprised of four components: cell membrane p22phox, electron 
transfer subunit gp91phox, and cytosolic subunits p47phox and p67phox[32].  NAD(P)H 
oxidase is regulated by many vasoactive agents including AngII[20].  Acute administration 
of AngII increases NAD(P)H oxidase activity [37].  The subcellular processes involved in 
AngII-mediated NAD(P)H oxidase activation have been linked to phospholipase A and D, c-
Src, RhoA, Rac and phosphatidylinositol 3-kinase[34].  In addition, chronic administration of 
AngII leads to de novo synthesis of NAD(P)H oxidase subunits[20].  Thus, exposure to high 
circulating and/or local vascular levels of AngII contributes to increased ROS production via 
NAD(P)H oxidase. 
 
ROS production and agonist-induced vasoconstriction 
A delicate balance between NO production and ROS production exists within the 
vasculature, contributing to the overall maintenance of vascular reactivity[38].  For example, 
ROS overproduction has been found to be a contributing mechanism to vasomotor 
dysfunction in hypertension[39].  When ROS production is increased, as in hypertension, the 
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shift to a pro-oxidant blood vessel environment disrupts function[40].  In addition to 
impairing agonist-induced vasodilation, excessive ROS production seems to exaggerate 
agonist-induced contractile responses in conduit vessels.  For example, Miyagawa et al. 
(2007) reported an amplified contractile response to norepinephrine (NE) in the femoral 
arteries of spontaneously hypertensive rats (SHR) [40].  Exaggerated vascular superoxide 
anion production, mostly accounted for by NAD(P)H, is observed in SHR [32] – suggesting 
a possible participation of ROS in increasing agonist-induced contractile responses in blood 
vessels.  Indeed, incubation of the aforementioned femoral arteries with 
diphenyleneiodonium (DPI) and apocynin, both NAD(P)H inhibitors, reduced the NE-
induced contractions in SHR[40].  Taken together it appears that ROS production, 
particularly superoxide anion, increases agonist-mediated contractile responses in SHR.  In 
addition, Yang et al. (2002) demonstrated that ROS is involved in endothelium-induced 
contractions evoked by ACh in SHR aorta [41].  Tiron, a cell-permeable non-enzymatic 
scavenger of superoxide anions, partly reduced the ACh-induced contractions in SHR aorta.  
Also incubation of SHR aorta with diethldithiocarbamic acid, which at certain concentrations 
can inhibit endogenous Cu/Zn superoxide dismutase (SOD), led to increased superoxide 
anion production but not an increase in acetylcholine (ACh)-induced contractions in 
SHR[41]; indicating that superoxide anions per se are not sufficient to evoke contraction, but 
may form other radicals that exaggerate contraction (i.e. hydroxyl radical).  Regardless of the 
specific mechanism utilized, it seems that ROS has the ability to reduce NO bioavailability 
and increase agonist induced vasoconstrictory responses. 
An interaction exists between AngII and adrenergic receptor stimulated contraction.  
Several reports indicate that AngII increases vascular reactivity to α-adrenergic stimulation 
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[42;43].  ACE inhibitor treatment in the drinking water of SD rats has been linked to reduced 
submaximal aorta contractions to phenylephrine (PE)[44].  Lemos et al. (2002) reported 
reduced in-vitro contractile responses to PE, in the aorta of SD rats, after a 30 minute 
incubation with the ACE inhibitor captopril in the organ baths [45].  In addition, Lemos et al. 
employed AT1 receptor blockade, with CV 11974, to further diminish aortic contractile 
responses to PE; thus signifying a role for AT1-mediated events, such as increased ROS 
production, in increased vascular reactivity.  Maeso et al. suggested that AT2 receptors are 
intricately involved in the ability of AT1 receptor blockade to attenuate α-adrenergic-
stimulated vasoconstriction since a known AT2 receptor blocker, PD 123319, abolished the 
attenuating effect of losartan (a specific AT1 receptor blocker) on PE mediated 
vasoconstriction [46].  Maeso et al. also reported that the NO synthesis inhibitor Nω-nitro-L-
arginine methyl ester (L-NAME) reversed the losartan-mediated reduction in PE 
vasoconstrictor responses[46]; also suggesting mediation by NO in the ability of AT1 
blockade to attenuate PE-mediated vasoconstriction.  An interesting relationship exists 
between AT2 receptor activation and the NO-cGMP axis [47].    Cosentino et al. (2005) 
revealed that losartan unmasked AT2 mediated vasodilation in the thoracic aorta of SHR rats 
that were administered AngII[48].  AT2 activation increased NO production which 
significantly, but not entirely, contributed to the beneficial hemodynamic effects of AT1 
receptor blockade.  Cosentino et al. also observed increases in an AngII breakdown product, 
Ang (1-7).  When the corresponding receptor for Ang (1-7), Mas receptor, was 
concomitantly blocked along with AT1 and AT2 receptors the vasoconstrictory attenuating 
effect of AT1 blockade was no longer observed[48].    Collectively these research results 
indicate that tissue AngII can affect α-adrenergic stimulation in the vasculature based on an 
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intricate balance between AT1 (ROS production) and AT2 activation (NO production) within 
the vascular wall. 
 
Exercise induced changes in ROS production and vascular wall RAS 
Research has identified various benefits for performing daily physical activity; among 
them being improved endothelium-dependent vasodilation[38].  Improvements in vasomotor 
function, following regular physical activity, are associated with improved NO 
bioavailability[39].  Adams et al (2005) reported a significant reduction in left internal 
mammary artery (LIMA) expression of NAD(P)H oxidase subunits, and NAD(P)H oxidase 
derived superoxide anion production, following chronic physical exercise[36].  In addition, 
downregulation of gp91phox mRNA expression and ROS production occurs in bovine aortic 
endothelial cells subjected to pulsatile shear stress[49], suggesting that decreased ROS 
production may improve function following chronic exercise.  Exercise causes acute 
increases in arterial laminar flow, leading to increased pulsatile shear stress, which stimulates 
the release of nitric oxide and other endothelium-derived relaxing factors to dilate the artery 
and restore shear stress toward normal[50].  Longer-term increases in flow produce changes 
in endothelial shape, alignment, and the expression of genes associated with a healthy 
phenotype including increased endothelial nitric oxide synthase (eNOS) expression, and as 
discussed above, decreased NAD(P)H subunit expression[50].  Thus, increasing evidence 
suggests that exercise training reduces ROS formation in the vessel wall by downregulating 
NAD(P)H oxidase activity and subunit expression, which increases NO bioavailability and 
improves vasomotor function.  
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AngII induces NAD(P)H activity via AT1, while AT2 stimulation counteracts the 
ROS production mediated through AT1.  Thus, the net effect of AngII depends mainly on the 
AT1/AT2 ratio in VSMC.  Adams et al (2005) documented a ~50% decrease in AT1 receptor 
protein expression in the LIMA of trained compared to untrained males, whereas AT2 
receptor protein expression remained the same (mRNA expression in trained males was ~5 
fold higher than untrained males) [36].  Thus, exercise may alter the AT1/AT2 ratio in the 
vasculature modifying the actions of locally produced AngII.  In addition, Kohno et al. 
discovered lower resting plasma AngII levels following chronic exercise[51], concluding that 
this was responsible for blunted ROS production, and the blood pressure lowering effect of 
10 weeks of training in SHR rats[51].  Thus, it is apparent that chronic exercise training 
reduces AT1/AT2 receptor ratio and circulating AngII, which contributes to the observed 
improvements in vasomotor function following exercise. 
Despite extensive research into chronic aerobic exercise, little is known about the 
modifications to circulating and vascular wall RAS following a single bout of exercise.  
During exercise a significant redistribution of tissue blood flow occurs, in which the blood 
flow to active muscles is increased whereas it remains the same or even decreased in less 
metabolically demanding areas such as the splanchnic circulation[52].  Although the 
exercise-induced redistribution of blood flow has been partly attributed to increased SNS and 
multiple metabolic factors[53], the precise mechanisms are not known.  Maeda et al. suggests 
that tissue production of various vasoconstrictor peptides within the vasculature participate in 
exercise-induced redistribution of blood flow[53].  For example, they observed an 
enhancement of endothelin-1 production in the non-exercising muscles of males performing 
one-legged cycling[54].  Maeda et al. also suggested a role for local RAS in redistributing 
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blood flow during exercise.  In a single bout of exercise (30m/min for 30min, 0% grade) 
male SD rats showed increased angiotensinogen levels, ACE mRNA expression, ACE 
protein expression and AII levels in the kidney[53].  The observed enhancement of kidney 
RAS led the group to conclude that the local RAS is involved in the tissue specific 
vasoconstriction, aiding blood flow redistribution during acute exercise[53].   
 Acute exercise also results in a variety of vascular functional alterations such as 
vasodilation-mediated post-exercise hypotension, increased vascular compliance, and altered 
vascular sensitivity to vasoactive substances[55-58].  It is well documented that a single bout 
of dynamic exercise reduces postexercise arterial pressure for several hours[55].  Rao et al. 
(2002) showed a reduced responsiveness of α-adrenergic receptors post exercise, which 
contributes to the observed postexercise hypotension[55].  NOS inhibition restored 
postexercise responses to PE, suggesting NO-induced vasodilation counters the PE induced 
vasoconstriction.  Indeed, human studies have shown increased NO production following 
exercise[59], indicating a role for NO-mediated vasodilation in post exercise hypotension.  
Acute exercise has also been shown to increase vascular compliance.  The effect of a single 
30-min bout of cycling exercise, at 65% of maximal oxygen consumption, on indexes of 
arterial compliance included reduced aortic and leg pulse-wave velocity (PWV) and 
decreased total peripheral resistance (TPR)  [56].  The decreases in vascular stiffness may be 
related to the increased production of NO.  NOS inhibition, by L-NMMA administration, 
was able to elicit increases in leg PWV during acute exercise[57], which suggest that 
increased production of NO may factor in to the decrease of regional arterial stiffness during 
a single bout of aerobic exercise.  Examination into the effects of acute exercise on 
vasomotor activity has revealed conflicting results.  For example, Howard et al. (1992) 
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showed that a single bout of exercise reduced maximal contractions to PE in the aorta of 
New Zealand White Rabbits[58].  Contractile responses to 70mM KCl were unchanged 
following exercise suggesting that dynamic exercise specifically attenuated α-adrenergic 
receptor-mediated contraction of VSMC.  Patil et al. (1993) also reported diminished 
maximal vasoconstrictor responses to PE in the hindlimb of acutely exercised SD rats[60].  
Surprisingly, L-NAME enhanced maximal PE constrictions in the hindlimb preparations 
mentioned above, suggesting that NO contributes to the reduction of vasoconstriction 
following exercise and α-adrenergic receptor stimulation[60].  In contrast, Spier et al. (1999) 
found that a single bout of exercise did not alter the SD abdominal aorta responsiveness to 
vasoconstrictor agonists (PE, NE, AVP, KCl)[61].  Thus, the experimental evidence stated 
above links acute exercise with functional vascular alterations such as vasodilation-mediated 
post-exercise hypotension and increased vascular compliance.  However, the effects of acute 
exercise on vasomotor properties remain disputed.  This disagreement may be related to the 
type of exercise employed, varied animal species and vascular beds. 
 
Experimental Study Outline 
 The purpose of this study was to determine whether acute exercise alters vascular 
RAS activity and if the alterations are associated with distinct vasomotor responses in the 
femoral arteries of Sprague Dawley rats.  Completion of the following 3 studies clarified 
whether:  (1) acute exercise alters femoral vascular wall RAS activity, (2) acute exercise 
alters vasomotor responses in femoral arteries, and (3) there is a link between altered 




Study 1: Measurement of changes in vascular RAS activity following acute exercise 
Maeda et al. (2005) reported an increase in kidney RAS activity following a single 
bout of exercise, which contributed to vasoconstriction of the renal vasculature.  Thus, it is 
possible that local blood flow conditions during exercise (i.e. blood flow is shunted to the 
working muscles while non-exercising areas, such as the splanchnic area, have decreased 
flow) are partially dependent upon, or cause alterations to, vascular wall RAS.  Pilot studies 
within our laboratory have determined that ACE protein and activity decrease in thoracic 
aorta following acute exercise, while increases are observed in kidney tissue.  Accordingly, a 
hypothesis can be made regarding acute exercise and the local femoral artery wall RAS.  
Since the femoral artery serves active tissues, which require higher blood flow during acute 
exercise, vascular RAS activity is hypothesized to be reduced either as a response to higher 
blood flow or to attenuate vasoconstriction and allow for higher blood flow to perfuse the 
active tissues.  To test this hypothesis, femoral arteries were excised immediately following 
exercise and snap frozen.  The alterations in femoral vascular wall RAS were evaluated in 
exercised rats by assessing vessel wall ACE activity and protein levels, and AT1 / AT2 
protein expression.     
 
Study 2:  Investigation of femoral artery vasomotor responses following an acute bout of  
   exercise 
 
Following an acute bout of exercise, femoral arteries were excised from Sprague 
Dawley rats and mounted on in-vitro myography baths to assess vasomotor function was 
assessed.  In accordance with the hypotheses made above, regarding vascular RAS and acute 
exercise, we expected to observe blunted α-adrenergic mediated vasoconstriction and 
14 
 
perhaps enhanced endothelium-dependent vasodilation in the femoral artery following an 
acute bout of exercise.  
 
Study 3: Examination of the role femoral vascular RAS plays in altered femoral artery  
  vasomotor responses following acute exercise 
 
Femoral arteries were incubated with a series of RAS blockers prior to performing 
vasoconstrictor and vasodilatory curves.   Pre-incubation with captopril, telmisartan, 
PD123319 and combinations of the three RAS blockers were used to ascertain the functional 
contribution of specific local vascular RAS components (ACE, AT1, and AT2 receptors, 
respectively) to altered femoral artery vasomotor function following exercise.  L-NAME, a 
nitric oxide synthase inhibitor, was also used in combination with certain RAS blockers to 
evaluate the possible relationship between NO and vascular RAS in determining femoral 
vasomotor properties.  We hypothesized that vessel wall RAS contributes in agonist induced 
vasoconstriction, and that the effects will be dependent on NO.  Specifically, following acute 
exercise, we hypothesize that ACEi and AT1 blockade will blunt α-adrenergic mediated 
vasoconstriction further than exercise alone in femoral arteries, and that the additional 
blockade of AT2 receptors should augment this blunted α-adrenergic mediated 










Figure 1: Circulating Renin-Angiotensin System. The formation of angiotensin II can arise 
through both an ACE-dependent pathway and ACE-independent pathway within the vessel 
wall.  Angiotensin II has effects systemically and locally, and can be inhibited by various 










Figure 2:  Local Vascular Wall Renin-Angiotensin System.  ACE-dependent angiotensin II 
formation has been identified in different layers of the vessel wall.  The formation of 
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 To draw blood via cardiac puncture, an incision was made along the midline through 
the sternum to open up the thorax and expose the beating heart.  An 18 gauge needle, which 
was attached to a 20cc syringe, punctured the right ventricle and blood was drawn.  
 To excise the femoral artery, an incision was made lateral to the midline of the rat 
opening an area between the leg and abdominal region.  Muscle fascia was separated from 
the leg muscles to expose the femoral vein, artery, and saphenous nerve complex.  The fascia 
connecting the abdominal wall and leg muscles was separated to expose the external iliac 
artery and vein.  The femoral nerve was removed starting from the branch point between the 
external iliac and femoral nerves.  Next, a section of vein, starting from above the branch 
point to a point where the femoral artery runs deep, was removed.  Finally, the femoral artery 
was removed and placed into a 4°C physiological buffer solution (131.5 mM NaCl, 13.5mM 
NaHCO3, 11.3mM glucose, 5.0mM KCl, 2.5mM CaCl2, 1.2mM NaH2PO4, 1.2mM MgCl2, 
and 0.025mM EDTA), and cleaned of surrounding fat and connective tissue.  Femoral artery 
rings used for the myography protocols were taken just distal to the branch point between the 
external iliac and femoral arteries.    
 
Catecholamines  
 Norepinephrine and epinephrine levels were determined by  high pressure liquid 
chromatography.  3mL of whole blood was collected via cardiac puncture from all rats.  
75µL of an antioxidant cocktail (6% EGTA and 9% Glutathione) was present during the 
collection.  The sample was then centrifuged for 10min at 3000g to yield a plasma fraction.  
The plasma was collected and stored at -80°C until time of assay.  The plasma extraction 
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process was as follows:  In a 1.5mL microcentrifuge tube, 1mL of plasma was added to 
20mg of acid washed alumina, 400µL 2.0M TRIS + 2% EDTA (pH 8.7), and 50µL of 3,4-
Dihydroxybenzylamine.  Following inversion for 10min, the alumina inside the 
microcentrifuge tube was washed with distilled water four times to ensure that the plasma 
inside the tube was completely rinsed out.  Next, 100µL of 0.1M Perchloric Acid was added 
to the microcentrifuge tube to elute the catecholamines from the alumina.  The 
microcentrifuge was vortexed, then centrifuged at 3000g for 10min.  50µL of the supernatant 
was injected into the chromatographic column.  Catecholamine levels were expressed in 
pg/mL. 
 
Study 1: Measurement of changes in vascular RAS activity following acute exercise 
Plasma and Tissue ACE Activity 
Circulating and vascular tissue ACE activity levels were evaluated using a 
spectrofluorimetric assay adapted from Schwager et al. [62].  A plethora of assays have been 
employed to examine ACE activity, including early in vitro bioassays and specific HPLC 
assays, however the protocol employed in this study allows for high-throughput and 
specificity[62].  A synthetic ACE substrate, L-Hip-His-Leu (HHL), was used in this assay.  
The artificial amino-substituted tripeptide has a free C-terminal end and a non-prolyl residue 
in the penultimate position akin to physiological substrates of ACE.  Once cleaved by plasma 
or tissue ACE, the remaining L-histidyl-L-leucine (HL) can be quantified flourimetrically by 




Plasma ACE:   2mL of whole blood was collected via cardiac puncture from all rats.  Whole 
blood was spun for 10min at 3000g to yield a plasma fraction.  Plasma was frozen 
immediately and stored until time of assay.  The assay was completed on a clear 96-well 
round bottom assay plate.  A standard curve was created, in triplicate, with various 
concentrations (0nM – 12nM) of HL.  Next, 30μL of HHL was be added to each well, and 
the entire plate was incubated at 37°C for 15min.  3μL of sample plasma was added to each 
well containing HHL, then mixed on an orbital shaker and incubated at 37°C for 30min.  
After incubation, 177μL of 0.28M NaOH was added to stop the ACE dependent enzymatic 
reaction.  To allow for fluorescence measurements, 15μL of O-phthaldialdehyde (20mg/mL 
MeOH) was added to each well, to form an adduct with HL, and mixed for 10min at room 
temperature.  25μL of 3M HCl was then added to each well to stop further fluorescent adduct 
formation.  The plate was mixed well and endpoint fluorescence was measured at an 
excitation wavelength of 360nm and emission wavelength of 485 nm.  Values obtained were 
expressed as nmol HL and conversion was necessary to achieve the accepted units for plasma 
ACE activity (expressed as μmol/min/L).   
 
Tissue ACE:   ~10mg of femoral artery tissue was homogenized in 10X volume of 0.02M 
potassium phosphate buffer with 0.1% triton X-100.  Samples were then centrifuged for 
10min at 3000g with the supernatant being collected and stored at -80°C until time of assay.  
The ACE activity assay was performed as stated above, with the only exception being the use 
of the homogenate instead of plasma.  Tissue ACE activity was expressed as μmol/min/mg 




Plasma AII levels 
5mL of whole blood was collected via cardiac puncture from all rats.  An inhibitor 
cocktail was included in the syringe to prevent any ex-vivo generation and/or degradation of 
AngII [63].  The inhibitor cocktail contained o-phenanthroline 0.44mM, EDTA 25mM, p-
hydroxy-mercuribenzoic acid 1mM, and pepstatin A 0.12mM (aforementioned 
concentrations are in the final sample volume).  The blood was then centrifuged at 3000g for 
20 minutes at 4°C.  Plasma samples were stored at -80°C until time of extraction.  AngII was 
extracted from the plasma prior to using a commercially available AngII enzyme 
immunoassay (EIA) kit (SPI-BIO, France).  Briefly, phenyl-bonded cartridges (GE 
Healthcare) were pre-washed with 1mL methanol, followed by 1mL of water.  2mL of 
plasma passed through each cartridge, followed by washing with 1mL of water.  AngII 
peptides were eluted from the phenyl cartridge with 0.5mL of methanol, and then spun in a 
vacuum centrifuge until methanol was evaporated.  The pellet was then reconstituted with 
0.5mL of buffer provided in the kit (EIA buffer), vortexed and centrifuged at 3000g for 10 
min at 4°C.  The AngII EIA is based on the immobilization of a specific monoclonal anti-
AngII from a 96-well plate.  After immunological reaction with AngII, the trapped molecule 
was covalently linked to the plate by glutaraldehyde via amino groups.  After washing and 
denaturing, AngII reacted with the acethlcholinesterase-labelled mAb, which is used as a 
tracer.  The AChE tracer acts on Ellman’s reagent to form a yellow compound, which can be 
quantified by spectrophotometry.  Known concentrations of AngII were used to develop a 
standard curve.  The amount of tracer bound to the well is proportional to the amount of 





Femoral artery tissue was homogenized in lysis buffer (20mM HEPES, 10mM NaCl, 
1.5mM MgCl, 1mM DTT, 20% Glycerol, 0.1% Triton X-100), and centrifuged at 4000g for 
10min at 4°C.  The supernatant was collected and protein concentrations were obtained via 
BCA protein assay reagents using bovine serum albumin (BSA) as a standard.  The remaining 
homogenate was stored at -80°C.  These samples were optimally diluted to 1μg/μL with lysis 
buffer and sodium dodecyl sulphate (SDS) buffer containing DTT.  After denaturing samples 
at 95°C for 5min, 30μL of the diluted sample (30μg of protein) was separated on a SDS-
polyacrylamide gel (7.5%).  Each sample was then transferred to a polyvinylidene difluoride 
(PVDF) membrane (40min at 25V).  The membrane was treated overnight with blocking 
buffer containing 10% skim milk in tris buffered saline with 0.05% Tween20 (TBS-T).  
Membranes were sequentially exposed to a primary antibody (contained in a 10% skim milk 
solution) for 1 h at room temperature, three wash sequences with TBS-T, and a horseradish 
peroxidase (HRP)-conjugated secondary antibody for 1h.  After the reaction, the membrane 
was washed 5 times with TBS-T and combined with enhanced chemiluminescence solution 
(GE Healthcare).  Signals were detected on the Syngene gel documentation system.  Primary 
antibodies applied included: polyclonal anti-ACE antibody (H-170), AT1 (N-10), and AT2 
(H-143) receptor antibodies (1 : 200 dilution with blocking buffer; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA).  Secondary antibodies applied included: anti-rabbit 
(sc-2304) and goat anti-rabbit (sc-2004) immunoglobulin (1 : 2500 dilution with blocking 







Study 2:  Investigation of femoral artery vasomotor responses following an acute bout of  
   exercise 
 
Myography Protocol 
The purpose for performing myography on the femoral arterial segments in this study 
was to quantify vasomotor function.  Femoral arteries were excised from CON of IPEx male 
SD rats, cleaned of surrounding fat and connective tissue, and cut into 2mm ring segments.  
Excised femoral artery rings were mounted on single wire myography systems (Model 310A, 
v2.03;  Danish Myo Technology, Denmark).  Due to size limitations in the femoral artery 
(internal diameter = 150μm), single wire myographs were employed (these myographs are 
able to investigate vessels with internal diameters as small as 100μm).  Thus, only two 
femoral artery rings could be used from each animal due to a limited number of single 
myographs available.   These femoral artery rings were held by two adjacent 30µm stainless 
steel wires running through the vessel lumen.  One wire was fixed to a micrometer to allow 
for adjustment of vessel lumen diameter and wall tension, while the other wire was linked to 
a force transducer.  Femoral rings were immersed in a 10mL bath containing 37°C 
physiological buffer solution (131.5 mM NaCl, 13.5mM NaHCO3, 11.3mM glucose, 5.0mM 
KCl, 2.5mM CaCl2, 1.2mM NaH2PO4, 1.2mM MgCl2, and 0.025mM EDTA) aerated with 
95%O2 - 5%CO2 air.  Isometric tension, in response to vasoactive compounds, was recorded 
at 100Hz sampling rate via a PowerLab system (AD Instruments, Boulder Springs, 
Colorado). 
 
Identification of Femoral Artery Optimal Length 
In vitro vasomotor function has been assessed in our laboratory on a number of vessel 
beds and rat species; however, myography protocols specified for the femoral arteries of SD 
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rats have not been previously developed.  Thus, a straightforward resting length tension 
relationship of the vessel was determined to find an optimal resting length (L0) for all future 
protocols to employ.  Determining Lo requires administration of 60mM KCl, a dosage that 
elicits voltage-mediated vasoconstriction, at various resting tensions until the developed 
isometric tension has reached a plateau.  More specifically, femoral were mounted, set to a 
resting tension of 100mg, and administered 60mM KCl.  After a washout period, the vessel 
resting tension was increased by 50mg to 150 and, again, the vessel was subjected to 60mM 
KCl.  This procedure was repeated (i.e. increasing resting tension by 50mg and 
administration of 60mM KCl) until a plateau or decrease in developed isometric tension had 
occurred.  Discovering the optimal length for these femoral artery rings eliminated ~2h from 
future extensive myography protocols involving vasoconstrictory and vasodilatory agonists, 
as well as in-bath drug interventions.  From pilot work completed in the laboratory I have 
determined that the L0 of SD rat femoral arteries to be used in this study translated to a 
resting tension of 300mg; a number which was used in studies throughout my thesis work. 
 
Assessment of electromechanical coupling and receptor-mediated vasoconstriction 
To assess electromechanical coupling, in exercised and non-exercised male SD rats, 
dose-response curves to KCl were performed.  Freshly excised femoral artery ring segments 
were set to the pre-determined L0 and subjected to increasing amounts of KCl 
(10,20,30,40,50,60,70,80,90,100; all in mM).  As developed isometric tensions plateaued at 
each concentration, subsequent KCl concentrations were administered until 100mM KCl was 
reached.  After a washout period, α-adrenergic receptor-mediated vasoconstriction was 
assessed.  PE was introduced into the tissue bath in increasing concentrations from 10-9M to 
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10-4M.  After the developed isometric tension had reached a plateau at a given concentration, 
the subsequent concentration was administered until 10-4M PE.  The following 
administration pattern was followed: 10-9M, 10-8.5M, 10-8M, 10-7M, 10-6.5M, 10-6M, 10-5.5M, 
10-5M, 10-4.5M, 10-4M. 
 
Assessment of endothelium-dependent and independent vasodilation 
 Prior to assessing endothelium-dependent vasodilation via ACh dose-response 
curves, vessels were set to L0 and pre-constricted with a concentration of PE that elicited 
~75-80% maximal KCl contraction.  These constriction conditions have been pre-determined 
in our laboratory to elicit vasoconstriction lasting at least 60min in quiescent rings (sufficient 
time needed to obtain an ACh dose-response curve) and it allows for decreases in developed 
isometric tension to be evaluated.  Cumulative doses of ACh (10-9M to10-4M) were 
introduced at half Log M concentrations.  To evaluate endothelium-independent vasodilation, 
rings were administered a maximal concentration of the NO donor sodium nitroprusside 
(SNP);  thus, after completion of the ACh dose-response curve, a 10-4M dose of SNP was 
administered to the femoral vessels which caused the vessels to fully dilate from the pre-
determined PE pre-constriction dosage.   
 
Study 3: Examination of the role that femoral vascular RAS plays in altered femoral artery  
  vasomotor responses following acute exercise 
 
To observe the involvement of local vascular RAS in femoral vasomotor function 
following acute exercise, femoral artery rings were subjected to various pharmacological 
treatments to manipulate specific components of the local RAS.  Pharmacological treatment 
was applied to randomly selected rings and allowed to incubate for 30min prior to 
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performing the various dose-response curves.  The drugs treatments used in study 3 are as 
follows: (i) no drug; ND, (ii) 10-5M of the ACE inhibitor captopril; CAP (iii) 10-5M  of the 
AT1 blocker telmisartan; TEL (iv) 10-5 of the AT2 blocker PD123319; PD (v) 10-5M captopril 
and 10-5M telmisartan; CAP+TEL (vi) 10-5M telmisartan and 10-5 PD123319; TEL+PD  (vii) 
10-5M telmisartan and 10-4 of the NOS inhibitor L-NAME; TEL+ L-NAME (viii) 10-4 L-
NAME; L-NAME.  
 
Statistics 
Vasoconstrictor dose-response curve data was measured as developed tension (peak 
constriction – resting tension) in milligrams.  Vasodilator curve data was measured as peak 
% dilation [(pre-constriction tension – tension at peak dilation)/(pre-constriction tension) X 
100%].  Dose-response curves were fit into a sigmoidal model with a bottom boundary of 0 
(GraphPad Prism, v5.0a, San Diego, CA).  Curve characteristics (maximal 
constriction/dilation, EC50 and area under the curve) were obtained from each femoral artery 
ring based on the fit sigmoidal curve.  Rings pre-incubated with L-NAME alone or in 
combination with other drugs had a non-sigmoidal response when subjected to increasing 
amounts of ACh.  Thus, the EC50 curve parameter from the ACh dose-response curve was not 
recorded for L-NAME rings; however, the max dilation and area under the curve was 
recorded and plotted.   
The curve characteristics were compared with a two-way ANOVA (exercise vs. drug 
pre-incubation, α=0.05) using SAS statistical software (v9.1, SAS Institute Inc., Cary, NC).  
Tukey’s HSD post-hoc test (α=0.05) was employed when significant differences were 
obtained.  When required, curve characteristics for both control and exercised animals were 
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analyzed using a one-way ANOVA (vs. drug pre-incubation, α=0.025).  Tukey’s HSD post-
hoc test (α=0.025) was employed when significant differences were obtained in the one-way 
ANOVA.  For rat characteristics, ACE activity, catecholamines, plasma AngII, and Western 
blot data, Student’s T-test for independent means was used (α=0.05).  Values are expressed 






















Sprague Dawley Rat Characteristics and Exercise Protocol Confirmation 
 There were no age differences recorded between control and acutely exercised SD 
rats.  In addition, no differences we observed between CON and IPEx SD rats in terms of 
body mass, left ventricular weight, right ventricular weight and kidney weight (Table 1).   
Exercise caused a significant increase in norepinephrine (Figure 3) and epinephrine (Figure 
4) levels for SD rats.  Norepinephrine rose approximately 87% in IPEx (n = 12) animals 
compared to CON animals (n = 14) (p = 0.04).  Epinephrine rose approximately 162% in 
IPEx (n = 15) animals compared to CON (n = 14) animals (p = 0.02).   
 
Plasma ACE activity and AngII levels 
 Plasma AngII levels were measured via a commercially available AngII enzyme 
immunoassay kit (Figure 5).  Plasma AngII levels were ~94% higher following exercise 
when compared to control levels (p = 0.03).  IPEx: 169.18 ± 32.63 pg/mL vs. CON: 97.20 ± 
14.78 pg/mL.  Plasma ACE activities were measured via a spectrofluorimetric assay adapted 
from Schwager et al.[62].  Plasma ACE activity (Figure 6) decreased by ~10% following 
acute exercise when compared to control (p = 0.03).  CON: 0.89 ± 0.02 µmol/min/L vs. 
IPEx: 0.80 ± 0.03 µmol/min/L. 
 
Femoral ACE activity 
Tissue ACE activities were measured (Figure 7), in excised femoral arteries from 
CON animals (n = 11) and IPEx animals (n = 11), by a spectrofluorimetric assay adapted 
from Schwager et al.[62].  Femoral ACE activity decreased after the acute exercise protocol 
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ACE (Figure 8), AT1 (Figure 9) and AT2 (Figure 10) receptor protein levels were 
measured in the femoral arteries of CON and IPEx animals via Western blotting.  Femoral 
ACE protein decreased after acute exercise by ~39% following the acute exercise protocol 
(CON: 1.09 ± 0.26 AU vs. IPEx: 0.66 ± 0.14 AU, p = 0.047).  Femoral AT1 protein levels 
did not change following exercise (CON: 2.32 ± 0.27 AU vs. IPEx: 2.07 ± 0.16 AU, p = 
0.44).  Femoral AT2 protein levels did not change following exercise (CON: 2.49 ± 0.26 AU 
vs. IPEx: 2.32 ± 0.27 AU , p = 0.65).   
 
 
Assessment of electromechanical coupling – KCl dose-response curves 
To assess electromechanical coupling, in exercised and non-exercised male SD rats, 
dose-response curves to KCl were performed.  Three curve characteristics were used to 
identify any possible differences due to exercise or drug pre-incubations (Table 2A).  These 
curve characteristics were the maximum vasoconstriction to KCl (MAX), half maximal 
effective concentration (EC50), and area under the curve (AUC).  No significant main effect 
of exercise (Figure 11) or interaction effects were observed for MAX, EC50 and AUC.  
However, a main effect of drug was observed for EC50 (p < 0.001).  Post-hoc tests revealed 
that pre-incubation with the nitric oxide synthase inhibitor L-NAME alone, and in 
combination with AT1 receptor blocker, telmisartan, caused a decrease in EC50 (Figure12, 




Assessment of α-adrenergic receptor-mediated vasoconstriction  
 Receptor-mediated vasoconstriction was assessed via dose-response curves to the α-
adrenergic receptor specific agonist PE.  Three curve characteristics were used to identify 
any possible differences due to exercise or pre-drug incubations (Table 3).  These curve 
characteristics were the maximum vasoconstriction to PE (MAX), the half maximal effective 
concentration (EC50), and area under the curve (AUC) (Tables 5/6).    Main effects of 
exercise (p = 0.01) and drug pre-incubation (p < 0.001) were observed for MAX.  There was 
a ~13% reduction in MAX following the acute exercise protocol when collapsed over all 
drug pre-incubation groups (Figure 13, CON: 2022.00 ± 66.85 mg vs. IPEx: 1766.82 ± 70.40 
mg).  Similar to MAX, there were significant main effects of exercise (p = 0.003) and drug 
pre- incubation (p < 0.001) for AUC.  AUC decreased ~17% following exercise (CON: 
3061.21 ± 121.21 AU vs. IPEx: 2536.69 ± 127.64 AU).  A main effect of pre-drug 
incubation for EC50 was observed (p = 0.04), however Tukey’s HSD post-hoc test revealed 
no differences in sensitivity to PE (p>0.05).   
Although interaction effects of drug pre-incubation and exercise were not statistically 
significant for MAX and AUC in the two-way ANOVA (p = 0.10, p=0.19), apparent 
differences observed in the plotted data and a p-value close to significance warranted further 
investigation.  Thus, a one-way ANOVA was performed for each exercise condition (CON 
and IPEx).  To ensure true effects of MAX were being observed, a Bonferroni corrected 
alpha of 0.025 (0.05 / # of comparisons) was used to evaluate significance for the one-way 
ANOVA and Tukey’s HSD post-hoc tests.  Both CON (p=0.02) and IPEx (p < 0.001) groups 
displayed significant pre-drug incubation effects (Table 4/5).  For simplicity, the following 
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sections address the changes in MAX only, since effects of drug pre-incubations are mirrored 
in AUC.    
 
A) Effect of individual RAS blocker pre-incubation on  PE maximal vasoconstriction 
The maximal response to PE after exercise and no drug pre-incubation was ~18%  
lower compared to control animals with no drug pre-incubation (Tables 6/7). AT1 blockade 
with telmisartan decreased MAX for CON by ~22% (p = 0.015) and decreased MAX for 
IPEx by ~31% (p = 0.016).  An interesting observation was noted, where AT1 blockade in 
CON elicited the same MAX as IPEx with no pre-drug incubation (p = 0.75) (Figure 14).    
ACE inhibition with captopril had no effect on MAX for CON (p = 0.69), but neared 
statistical significance in IPEx animals (p = 0.04) (Figure 15).  In addition, AT2 receptor 
blockade with PD123319 had no further effect on MAX for both CON (p = 0.56) and IPEx 
animals (p = 0.83) (Figure 16).   
 
B)  Effect of combined RAS blocker pre-incubation on PE maximal vasoconstriction 
Combined ACE inhibition, with captopril (CAP), and AT1 receptor blockade, with  
telmisartan (CAP+TEL), decreased MAX for CON by ~29% (p = 0.01) and ~30% for IPEx 
(p = 0.01) when compared to ND (Figure 17).  CAP+TEL was, however, no different from 
TEL pre-incubation alone for both CON (p = 0.61) and IPEx (0.95).  Interestingly, 
CAP+TEL was significantly lower from CAP alone in CON animals (p = 0.01), but not in 





Combined AT1 and AT2 receptor blockade (TEL+PD) significantly decreased MAX 
in CON animals (p = 0.02), but not in IPEx animals (p = 0.97).  TEL+PD was not 
significantly different from TEL alone in CON animals (p = 0.75), while TEL+PD increased 
MAX by ~31% in IPEx animals (p = 0.025) when compared to TEL alone.   Interestingly, 
the MAX elicited by TEL alone for CON is no different from TEL+PD in IPEx animals (p = 
0.76) (Figure 18). 
 
C)  Effect of nitric oxide synthase inhibition on PE maximal vasoconstriction  
 NOS activity was inhibited by pre-incubation with 10-4 Nωnitro-L-arginine methyl 
ester (L-NAME), for 30min, prior to the construction of PE dose-response curves.  L-NAME 
incubation had no effect on MAX in CON animals (p=0.99), while L-NAME increased 
MAX by ~29% in IPEx animals (p = 0.002) when compared to ND.  Interestingly, the MAX 
elicited by CON with no pre-drug incubation was not significantly different from MAX 
elicited by L-NAME in IPEx (p = 0.15) (Figure 19).   
 Combined NOS inhibition and AT1 receptor blockade eliminated the attenuating 
effects of TEL alone for IPEx animals (p < 0.001) and CON animals (p = 0.02.  A special 
note, there is no difference observed in MAX PE elicited by TEL+L-NAME between CON 
and IPEx  (p = 0.84) (Figure 20). 
 
Assessment of endothelium-dependent vasodilation – ACh dose-response curves 
        Endothelium-dependent vasodilation was assessed via dose-response curves of the 
muscarinic receptor agonist ACh.  Rings were subjected to a 10-5.5 dose of phenylephrine to 
cause a pre-constriction level equal to ~75-80% max constriction from which the dilatory 
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curve could be produced.  Three curve characteristics were used to identify any possible 
differences due to exercise or pre-drug incubations (Table 8).  These curve characteristics 
were the maximum vasodilation to ACh (MAX), the half maximal effective concentration 
(EC50), and area under the curve (AUC) (Table 9/10).  There was a main effect of drug on 
MAX (p < 0.001), EC50 (p = 0.02), and AUC (p < 0.001).  There was no main effect of 
exercise (Figure 21) or interaction effects observed for MAX, EC50, or AUC.  For simplicity, 
the following sections will highlight the differences in pre-drug incubation on EC50 and 
MAX compared to no drug pre-incubation, since AUC changes reflect those seen in MAX. 
 
A)  Effect of individual RAS blocker pre-incubations on ACh vasodilation 
The only individual RAS drug pre-incubation that was able to alter MAX was the 
AT1 receptor blocker telmisartan (Figure 22, p = 0.01).  CAP and PD alone were not able to 
alter MAX (Figure 23, p = 0.38 and Figure 24, p=0.71).    The only individual RAS drug pre-
incubation that was able to alter EC50 was the AT2 receptor blocker PD123319 (Figure 24, p 
= 0.03).  CAP and TEL pre-incubations did not alter EC50 (p = 0.20, p = 0.12).   
 
 B)  Effect of combined RAS blocker pre-incubations on ACh vasodilation 
 ACE inhibition in combination with AT1 receptor blockade (CAP+TEL) did not alter 
MAX, EC50, or AUC any differently than TEL alone (Figure 25, p > 0.05).  Combined AT1 
and AT2 receptor blockade (TEL+PD) decreased MAX compared to AT1 blockade alone 
(Figure 26, p = 0.05).  MAX elicited by TEL+PD pre-incubation was not significantly 





C) Effect of nitric oxide inhibition on ACh vasodilation. 
EC50 was unable to be calculated for ACh dose-response curves with L-NAME or 
TEL+L-NAME pre-incubation due to the flat curve shape.  MAX was decreased 
significantly NOS inhibition.  L-NAME decreased MAX by ~83% (Figure 27, p < 0.001) 
and TEL+L-NAME decreased MAX by ~90% (Figure 28, p < 0.001).      
 
Assessment of endothelium-independent vasodilation to SNP 
 Endothelium-independent vasodilation was assessed by administering a maximal 
dose (10-4) of the NO donor SNP.  This maximal dose was administered following the 
completion of the ACh dose-response curve.  As seen in figure 29, endothelium-dependent 














Table 1: Sprague Dawley Rat Characteristics  
Characteristic CON n IPEx n p-value 
Age (wks) 19.01±0.21 40 19.10±0.20 39 0.992 
Body Mass (g) 453.32±6.52 40 450.99±5.43 39 0.785 
LV weight (g) 1.43±0.03 39 1.41±0.02 39 0.691 
RV weight (g) 0.23±0.01 39 0.25±0.02 39 0.361 
Kid weight (g) 0.94±0.01 39 0.91±0.02 39 0.236 
 
Values are stated as means ± s.e.m.  CON, control animals; IPEx, immediately post-exercise 
animals; LV, left ventricle; RV, right ventricle; Kid, kidney.  p-value obtained by Student’s 



















Figure 3: Norepinephrine levels increase after acute exercise.  Norepinephrine levels were 
obtained via high pressure liquid chromatography.  SD rats that underwent the acute exercise 
protocol had increased levels of norepinephrine (~87%; p = 0.04) compared to control 
animals.  IPEx: 767.73 ± 148.28 pg/mL vs. CON: 411.18 ± 82.85 pg/mL.  Values are 
expressed as means ± s.e.m., n = 12-15 per exercise condition.  p-value obtained by Student’s 






















Figure 4: Epinephrine levels increase after acute exercise.  Eprinephrine levels were 
obtained via high pressure liquid chromatography.  SD rats that underwent the acute exercise 
protocol had increased levels of epinephrine (~162%; p = 0.02) compared to control animals.  
IPEx: 1635.3 ± 352.01 pg/mL vs. CON: 625.02 ± 145.09 pg/mL. Values are expressed as 






















Figure 5: Plasma angiotensin II levels increase following acute exercise.  Plasma AngII 
levels were measured via a commercially available AngII enzyme immunoassay kit (SPI-
BIO, France).  Plasma AngII levels were ~94% higher following exercise when compared to 
control levels (p = 0.03).  IPEx: 169.18 ± 32.63 pg/mL vs. CON: 97.20 ± 14.78 pg/mL.  
Values are expressed as means ± s.e.m., n = 18-19 per exercise condition.  p-value obtained 

























Figure 6: Plasma ACE activity is reduced following acute exercise.  Plasma ACE activities 
were measured via a spectrofluorimetric assay adapted from Schwager et al. (2006).  Plasma 
ACE activity decreased by ~10% following acute exercise when compared to control (p = 
0.03).  CON: 0.89 ± 0.02 µmol/min/L vs. IPEx: 0.80 ± 0.03 µmol/min/L.  Values are 
expressed as means ± s.e.m., n = 13-15 per exercise group.  p-value obtained by Student’s T-

































Figure 7: Femoral ACE activity decreases following acute exercise.  Tissue ACE activities 
were measured, in excised femoral arteries from CON animals (n = 11) and IPEx animals (n 
= 11), by a spectrofluorimetric assay adapted from Schwager et al. (2006).  Femoral ACE 
activity decreased after the acute exercise protocol by ~20% (p = 0.04).  CON: 0.74 ± 0.05 
µmol/min/g protein vs. IPEx: 0.59 ± 0.05 µmol/min/g protein.  Values are expressed as 




































Figure 8: Femoral ACE protein levels decrease following acute exercise. Femoral ACE 
protein levels were measured via Western blot analyses.  Femoral ACE protein decreased 
after acute exercise by ~39% following the acute exercise protocol (p = 0.047).  CON: 1.09 ± 
0.26 AU vs. IPEx: 0.66 ± 0.14 AU.  Values are expressed as means ± s.e.m..  p-value 





Figure 9: Femoral AT1 protein levels are unchanged following acute exercise. Femoral AT1 
protein levels were measured via Western blot analyses.  Femoral AT1 protein levels did not 
change following exercise (p = 0.44).  CON: 2.32 ± 0.27 AU vs. IPEx: 2.07 ± 0.16 AU.  






Figure 10: Femoral AT2 protein levels are unchanged following acute exercise. Femoral 
AT2 protein levels were measured via Western blot analyses.  Femoral AT2 protein levels did 
not change following exercise (p = 0.65).  CON: 2.49 ± 0.26 AU vs. IPEx: 2.32 ± 0.27 AU.  





















Table 2: Electromechanical coupling to potassium chloride (KCl) 
A 
KCl  p-values  
 Drug Exercise Drug*Exercise 
MAX (mg) 0.96 0.25 0.82 
EC50 (mM)    <0.001 0.22 0.08 






















EC50 (mM) 45.47 ± 1.51 45.42 ± 1.58 38.66 ± 1.53 
 
A   p-values obtained from two-way ANOVA. Main effect of drug on Log EC50. No main effect of drug on KCl 
max constriction (MAX) and area under curve (AUC).  No main effect of exercise on MAX, Log EC50, and 
AUC.  No interaction effects seen in MAX, Log EC50, and AUC.  MAX: max constriction, AUC: area under 
curve, AU: arbitrary units.  B Log EC50 values from single drug conditions. C Log EC50 values from 
combination drug conditions.  Log EC50 values of ND, CAP, TEL, PD, CAP+TEL, and TEL+PD were 
significantly different from L-NAME and TEL+L-NAME values (p<0.05).  No difference was observed 
between L-NAME and TEL+L-NAME (p>0.05).  * significantly different from L-NAME. # significantly 






Figure 11:  No differences in CON and IPEx KCl dose-response curves.  Femoral artery 
rings from CON (•, n=52) and IPEx animals (○, n=43) were mounted on single wire 
myographs and set to the pre-determined L0 = 300mg.  Differences between CON and IPEx 
electromechanical coupling was assessed via a KCl dose-response curve.  No differences 
were seen between CON and IPEx electromechanical coupling (exercise main effect, p = 
0.25).  Curve characteristics were (1) MAX (CON: 1859.66 ± 73.87mg vs. IPEx: 1983.79 ± 
77.29mg), (2) EC50 (CON: 43.26 ± 0.75 mM vs. IPEx: 44.60 ± 0.78mM), (3) AUC (CON: 
104579.79± 4342.39 AU vs. IPEx: 108892 ± 4537.94 AU).  Values are expressed as means ± 
s.e.m. p-value obtained from two-way ANOVA.    
 






















Table 3: Phenylephrine dose-response curve – p-values from two-way ANOVA 
PE  p-values  
 Drug Exercise Drug*Exercise 
MAX (mg) <0.001 0.01 0.10 ^ 
EC50 (LogM)    0.04 0.12 0.92 
AUC (AU) <0.001 0.003 0.19 ^ 
 
p-values obtained from two-way ANOVA. Main effect of drug and exercise on MAX PE 
constriction was significant.  No main effect of exercise on EC50.  However, drug main effect 
was observed for EC50.  Main effects of drug and exercise on AUC were significant.  
^Drug*Exercise interaction effect was not significant (p = 0.10, 0.19), but was further 
investigated via one-way ANOVA, see text for details.     
 
 
Table 4:   Phenylephrine dose-response curve – p-values from one-way ANOVA for MAX PE 
 






p-values obtained from one-way ANOVA performed for CON and IPEx groups evaluating 
differences due to drug condition.  Both CON and IPEx groups have significant drug effect.  
A Bonferroni-adjusted alpha was used (α = 0.025). 
   
 
Table 5:   Phenylephrine dose-response curve – p-values from one-way ANOVA for AUC 
 






p-values obtained from one-way ANOVA performed for CON and IPEx groups evaluating 
differences due to drug condition.  Both CON and IPEx groups have significant drug effect.  











Figure 13: Acute exercise effect on max α-adrenergic receptor-mediated constriction.  
Femoral artery rings from CON and IPEx animals were mounted on single wire myographs 
and set to the pre-determined L0 = 300mg.  Differences between CON (n=53) and IPEx 
(n=42) α-adrenergic receptor-mediated contraction was assessed via a PE dose-response 
curve.  A significant difference were observed between CON and IPEx phenylephrine 
constriction (exercise main effect, p = 0.01).  Curve characteristics obtained were (1) MAX 
(CON: 2022.00 ± 66.85 mg vs. IPEx: 1766.82 ± 70.40 mg), (2) EC50 (CON: -5.49±0.04 
LogM vs. IPEx: -5.39±0.04 LogM), (3) AUC (CON: 3061.21±121.21 AU vs. IPEx: 
2536±127.64 AU).  Values are expressed as means ± s.e.m. p-value obtained from two-way 
ANOVA.     
 






































Table 8: Endothelium-dependent relaxation to acetylcholine (ACh) 
 
ACh  p-values  
 Drug Exercise Drug*Exercise 
MAX (% dilation) <0.001 0.33 0.77 
EC50 (LogM)    0.02 0.37 0.09 
AUC (AU) <0.001 0.57 0.45 
 
p-values obtained from two-way ANOVA. Main effect of drug on maximum dilation (MAX), 
EC50, and area under curve (AUC). No main effect of exercise across curve characteristics.  
No interaction effect seen across curve characteristics. on KCl max constriction (MAX) and 













Figure 21: No exercise effect observed in max endothelium-dependent vasodilation to 
acetylcholine.  Femoral artery rings from CON (•, n=52) and IPEx animals (○, n=43) were 
mounted on single wire myographs and set to the pre-determined L0 = 300mg.  Rings were 
subjected to a 10-5.5 dose of phenylephrine to cause a pre-constriction level equal to ~75-80% 
max constriction.  From the pre-constricted state, femoral artery rings were subjected to 
increasing doses of acetylcholine (ACh) to cause endothelium-dependent vasodilation.  
There was no significant effect of exercise on ACh dose response curve characteristics MAX 
(p = 0.33), EC50 (p = 0.37), AUC (p = 0.57) (MAX; maximum dilation, EC50, area under 
curve (AUC)).  p-values were obtained from two-way ANOVA. 
 






































































































































































































































































Acute exercise induced alterations in circulating RAS 
Modifications to circulating and vascular RAS components, stemming from chronic 
exercise training, have been previously researched[36;51]. However, little is known about the 
alterations to circulating and vascular wall RAS following a single bout of exercise.  This 
study evaluated several RAS components from the plasma (representing the systemic RAS) 
and femoral artery (representing the vascular wall RAS) of 18-20wk Sprague Dawley rats.  
Treadmill running for 1h, at a speed of 21m/min and 15% grade, increased plasma AngII 
levels by approximately 94%.  Increases in plasma AngII following exercise have been 
observed in other species, including humans[64].  Exercise can stimulate AngII production 
through several mechanisms.  AngII is known to regulate not only blood pressure, but also 
fluid and electrolyte homeostasis.  Although sweating during exercise helps regulate core 
temperature, excessive sweating leads to a loss of sodium and fluid volume.  To counteract 
the fluid and electrolyte loss, AngII levels increase which give rise to increasing levels of 
aldosterone[65].  Aldosterone stimulates water and salt intake to maintain appropriate fluid 
and electrolyte balance during exercise.  Another mechanism, involving sympathetic 
activation during exercise, leads to an increase in plasma AngII.  The kidney receives both 
sympathetic and parasympathetic fibres, but sympathetic neurons are more prominent[66].  
Sympathetic stimulation of the kidney, specifically the juxtaglomerular apparatus, leads to 
the secretion of renin.  Secreted renin enters the circulating blood where it is converted, 
ultimately, to AngII.  Sympathetic activation was identified clearly in our study via the rise 
in catecholamine levels.  Norepinephrine and epinephrine rose approximately 87% and 
162%, respectively.   
71 
 
Although ACE catalyzes the conversion of AngI to AngII in the circulation, an 
approximate 10% decrease in plasma activity levels was observed after exercise in this study.  
The observation of decreased plasma ACE activity seems to conflict with the rise in AngII 
following acute exercise.  It may be possible that, following exercise, AngII production 
within the circulation is directed mainly by non-ACE dependent mechanisms.  A significant 
proportion (~40%) of AII is formed by non-ACE dependent pathways, either from 
angiotensinogen by the enzymes cathepsin G, elastase, and tissue plasminogen activator, or 
from angiotensin I by enzymes including chymase[24].  In addition, a negative feedback 
mechanism occurs in the circulation during high exposure to AngII, whereby ACE 
production is halted to prevent further increases in AngII.  Therefore, it may be also possible 
that ACE enzymatic activity is reduced to further oppose the rise in AngII following 
exercise.  This possibility becomes more apparent when femoral ACE activity and protein 
levels are discussed. 
 
Acute exercise induced alterations in femoral vascular wall RAS 
Current research suggests that tissue production of various vasoconstrictor peptides 
within the vasculature may participate in exercise-induced redistribution of blood 
flow[53;54] .  Maeda et al. observed enhancements in kidney RAS following acute exercise, 
including increased angiotensinogen levels, ACE mRNA expression, ACE protein 
expression and AII levels, and suggested that these RAS alterations may play a role the 
redistribution of blood flow.   Thus, we expected to observe decreases in ACE activity and 
expression following a bout of exercise in our 18-20wk old rats.  Indeed, a ~20% decrease in 
femoral ACE protein expression and a ~40% decrease in femoral ACE activity was observed 
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following acute exercise.  However, no changes were observed in AT receptor expression 
following the acute bout of exercise.  The decrease in femoral ACE expression and activity 
observed in this study seems to follow the hypothesis that vascular RAS plays an important 
role in the redistribution of blood flow during exercise.  A decrease in ACE activity would 
presumably lead to decreased AngII production and less vasoconstriction; although, some 
characteristics of the ACE enzyme must be considered before jumping to these conclusions.  
ACE is able to produce AngII and breakdown the vasodilatory peptide bradykinin.  Thus, the 
exercise induced decrease in femoral ACE could potentially prevent AngII production and 
potentiate vasodilatory responses in the localized region.   In addition, the majority of ACE 
exists as an ectoenzyme anchored in the endothelial membrane[67].  ACE can be ‘shed’ from 
the membrane, by a class of proteases known as secretases, and circulate as soluble 
ACE[24].  Very few studies have identified whether ACE secretase activity is altered 
following an acute bout of exercise[68;69].  However, an interesting discovery of ACE 
shedding resulting from additional shear stress experienced at the surface-fluid interface 
during exercise was made by Rieder et al. (1997).  This group observed a decreased ACE 
activity in bovine pulmonary artery endothelial cells following 8 hours of shearing (20 
dyne/cm2)[70].  Thus, the decreased femoral ACE activity we observed could potentially be 
an artifact of increased shedding due to increased shear stress produced during exercise.  
Investigation of femoral artery vasomotor function following exercise with RAS 
pharmaceutical intervention, discussed later, will help clarify whether this reduction in ACE 
expression and activity is functionally important. 
 The vascular AT1/AT2 receptor ratio is a very important determinant of local AngII 
action[36].  A key benefit of regular physical activity may include a reduction in AT1/AT2 
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receptor ratio, whereby less negative AT1 receptor-mediated events occur and more positive 
AT2 receptor counteraction is uncovered.  This study revealed that no change occurs in AT1 
and AT2 receptor expression, and thus AT1/AT2 ratio following a single bout of exercise (at 
least immediately after).  Therefore vascular events mediated by AT receptors, such as 
vasomotor activity, should be unaltered so long as AngII levels and AT1 receptor signaling 
remain the same. 
 
Acute exercise, femoral RAS and vasoconstriction 
The advantage of using an in-vitro preparation to study alterations in vascular 
responsiveness following exercise is that potentially confounding neural, humoral, and 
metabolic influences present in-vivo can be eliminated[64].  This apparent advantage also 
permits the study of local vascular RAS isolated from the circulating systemic RAS.  KCl 
dose-response curves were completed to investigate whether exercise or RAS drug pre-
incubations would alter electromechanical coupling, and thus the overall ability of the vessel 
to contract.  The maximal responses to KCl were not significantly different between CON 
and IPEx.  Spier et al. (1999) also observed no changes in SD rat KCl constriction following 
treadmill exercise for 1h at 30m/min[61].  There were also no differences in maximal KCl 
responses with all drug pre-incubations.  Hence, any effects seen in PE vasoconstriction 
would be a result of isolated effects of exercise or vascular RAS on α-adrenergic receptor or 
the signaling pathway initiated by the receptors. 
 In this study, a significant decrease in maximum PE constriction was observed for 
acutely exercise animals when collapsed over all drug conditions (~13%) and in the no drug 
pre-incubation condition (~18%).  These findings, paired with the observed maintenance of 
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maximum constriction to KCl mentioned above, indicate that an acute bout of exercise is 
able to attenuate α-adrenergic receptor-mediated vasoconstriction.  The lowered 
vasoconstrictor responsiveness of the arterial vasculature has been high debated, especially in 
the realm of whether it ultimately contributes to post-exercise hypotension[61].  Spier et al. 
(1999) did not observe any changes in SD abdominal aortic sensitivity or maximal 
contraction to PE.  However, Howard et al. (1992) have shown that PE-evoked tension of 
aortic ring segments is diminished after a single bout of exercise in rabbits[58].  In addition, 
studies on SD rats are consistent with this notion of reduced adrenergic receptor 
responsiveness (termed sympatholysis), suggesting that it could carry forward into the post-
exercise period and contribute to post-exercise hypotension[55;60].  Both authors considered 
it a possibility that ineffective transduction of sympathetic outflow into vascular resistance 
could result from competing influences at the level of the arterial smooth muscle, such as the 
release of local vasodilator substances.  Although we cannot extend our findings to post-
exercise hypotension (blood pressure measurements were not made) we can definitely 
comment on the in-vitro vasomotor experiments observed in this study.   
The decreases in femoral ACE expression and activity may help explain the observed 
reduction in maximum PE constriction following exercise.  Decreased ACE activity would 
presumably lead to a reduced production of AngII.  Local AngII is known to facilitate 
adrenergic transmission in rat mesenteric arteries[71]. Decreased production of AngII can 
have profound effects since less AT1 receptor-mediated events would occur.  Mainly, 
reduced AT1-mediated ROS production would occur; AT1 is known to activate NAD(P)H 
oxidase[41] leading to the production of superoxide anion and other ROS[34].  Blockade of 
AT1 receptors has been shown to diminish contractile responses to PE in the aorta of SD 
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rats[45] and SHR rats[46].  Reduced maximum constriction to PE during AT1 receptor 
blockade has been replicated in our study of femoral arteries.  Thus, lowered AT1 receptor 
stimulation following acute exercise (due to the decreased ACE-dependent AngII 
production) could contribute to the reduced PE-mediated constriction observed in this study.  
Another possible link between post-exercise decreases in ACE activity and PE-mediated 
constriction exists through the vasodilator bradykinin.  Shear stress activates the local 
kallikrein-kinin system in the arterial wall, which has powerful vasodilator properties mainly 
through the peptide bradykinin[44].  The role of bradykinin in vasomotion depends highly on 
its rate of production by kininogenases and degradation by ACE.  Although ACE is most 
known for its participation in AngII production, the active enzymatic site can also cleave 
bradykinin at the penultimate amino acid and inactivate it[67]. Thus, increased bradykinin-
mediated vasodilation and reduced ACE activity during both ACE inhibitor treatment or 
exercise (as indicated in this study) may explain the observation of reduced PE-mediated 
vasoconstriction. 
 Whether or not decreased ACE activity is responsible for the reduced PE-mediated 
vasoconstriction, the exercise effect observed in this study is NO-dependent.  When IPEx 
femoral rings were pre-incubated with the NOS inhibitor L-NAME alone, or in combination 
with other drugs, the attenuated PE constriction disappeared.  In addition, L-NAME pre-
incubations elicited similar maximum PE constrictions in IPEx animals resembled CON 
animals.  Hemodynamic shear stress on the arterial wall is known to be an important 
modulator of NO release[38]. Increments of blood flow through arteries in-situ[60] or in-
vitro[72] can induce immediate vasodilation that is reduced by NOS inhibitor or abolished by 
removal of the endothelium.  As mentioned above, decreased ACE activity can reduce NO 
76 
 
degradation or promote NO production.  Decreased AT1 receptor stimulation by local AngII 
increases NO bioavailability due to lower rates of AT1-mediated ROS quenching of NO.  
Decreased ACE activity also reduces bradykinin degradation; activation of bradykinin 
receptor B2 phosphorylates eNOS[48], which leads to NO production.  A crosstalk between 
bradykinin receptor B2 and RAS exists. Both the AT2 receptor and the Mas receptor for 
Ang(1-7) are able to signal and activate the B2 receptor[48].  This study revealed no changes 
to AT2 expression following exercise.  In addition, blockade of the AT2 receptor with 
PD123319 following exercise had no significant effect.  However, the combination of AT1 
and AT2 blockade eliminated the attenuating effect of isolated AT1 blockade in the exercise 
animals suggesting that the AT2 effects are unmasked or perhaps sensitized only during 
exercise and AT1 blockade (figure 18)  – which coincides with the literature on AT receptor 
blockade[45;46].  The specific contribution of Ang(1-7) to post-exercise reductions in max 
PE constriction was not studied, although the vasodilator peptide has been shown to augment 
α-adrenergic constriction[45;48].   
 
Acute exercise, femoral RAS and vasodilation 
 SNP Dose-response curves were completed to evaluate whether exercise or RAS drug 
pre-incubations modulated signaling downstream of NO.  No differences in maximum 
dilation to SNP were observed across all exercise and drug conditions.  Thus, the responses 
of femoral artery rings to ACh are not likely due to alterations in signaling downstream of 
NO, but rather are endothelium dependent.   
     ACh dose-response curves were created to evaluate the effect of exercise and RAS 
drug pre-incubations on endothelium-dependent vasodilation.  Both sensitivity and maximal 
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responses to ACh were not different after a single bout of exercise.  Studies have evaluated 
the time course of endothelium adaptation to exercise.  Delp and Laughlin (1997) reported 
that enhanced endothelium-dependent dilation in the aorta of male SD rats was seen after 
four weeks of training[73].  Haram et al. (2006) also reported no changes in ACh-mediated 
dilation immediately following exercise in female SD rats[74].  This study displays that no 
change in femoral artery endothelium-dependent vasodilation occurs immediately after a 
single bout of exercise. 
 Some important facts about the femoral artery were discovered from the effect of 
various drug pre-incubations on ACh-mediated vasodilation.  First, whether or not the animal 
was exercised, L-NAME significantly reduced the ACh-mediated vasodilation. After NOS 
inhibition, the femoral arteries were only able to dilate about 10% from the PE pre-
constricted state.  These results suggest that the major component of endothelium-dependent 
vasodilation in the femoral arteries, as with other conduit arteries, is mediated by NO.  Shi et 
al. (2006) also reported the predominance of NO in femoral artery endothelium-dependent 
vasodilation[75].  Second, the femoral artery reacts similarly to AT receptor blockade as the 
aorta and other conduit vessels.  When femoral arteries were pre-incubated with telmisartan, 
an AT1 receptor blocker, vasodilation to ACh was enhanced.  This is in agreement with other 
studies performed on SD aorta[76] and SHR aorta[48], whereby the authors attributed the 
effect of AT1 blockade to enhanced AT2 activation.  This unmasking of AT2 dilation during 
AT1 blockade was observed in this study, as the improved vasodilation vanished with 
combined AT1 and AT2 receptor blockade.  Lastly, when the femoral arteries of CON 
animals were pre-incubated with the ACE inhibitor captopril, no significant changes in ACh-
mediated dilation were observed.  This leaves the possibility that local AngII production in 
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the femoral artery is moderately dictated by non-ACE dependent mechanisms; however, this 
postulation cannot be valid without actual measurement of tissue AngII with and without 






















Due to technical limitations local tissue AngII production could not be measured, 
only implied.  The commercially available AngII enzyme immunoassay kit used in this study 
requires 2mL of sample to properly extract AngII peptides.  This volume was obtained for 
plasma samples; however for tissue homogenate, pooling of multiple samples would have 
been required (one entire femoral artery yields ~150µL of homogenate with 3µg/µL protein 
concentration).  The amount of AngII peptide would be untraceable if it was gathered from a 
single homogenate.  Other studies have evaluated tissue AngII levels by infusing radio-
labeled AngI and measuring the radio-labeled AngII[77].  The process requires SepPak 
extraction and high-perfromance liquid chromatography separation.  In addition, losses in 
AngII peptides have been reported to be ~20-30% in tissue homogenate after extraction and 
separation[77].  Thus, due to unfamiliar and imprecise methods, tissue AngII production was 
implied from the myography data. 
 Another limitation of this study was the inability to determine whether the alterations 
in femoral RAS were responsible for increasing blood flow to the hind-limbs during exercise.  
Blood flow following acute exercise was not measured in this study, however vasomotor 
function was assessed. The advantage of using an in-vitro preparation to study alterations in 
vascular responsiveness following exercise is that potentially confounding neural, humoral, 
and metabolic influences present in-vivo can be eliminated[64].  Thus, the data acquired 
from the various RAS drug conditions can be used to explain the role of femoral RAS plays 






The aim of this study was to examine whether a single bout of exercise alters vascular 
RAS in the femoral artery, and if these alteration would lead to a functional change in the 
vasomotor properties of the vessel.  The main findings of this study are: 
1) A single bout of exercise reduced the femoral artery ACE expression and activity. 
2) A single bout of exercise attenuated the α1-adrenergic receptor-mediated 
vasoconstriction, but this effect was abolished with NOS inhibition. 
3) The reduction in α1-adrenergic receptor-mediated vasoconstriction may be linked to 
the decreased activity of femoral ACE, which supports the production of local 
vasodilatory factors. 
4) A single bout of exercise did not alter femoral artery endothelium-dependent 
vasodilation to acetylcholine or vascular smooth muscle sensitivity to exogenous NO.   
5) Femoral artery vasodilation was modulated by AT1 receptor blockade, whereby AT1 
blockade unmasked AT2 receptor-mediated events. 
6) For α1-adrenergic receptor-mediated vasoconstriction, only exercised animals 
displayed sensitivity of AT2 receptor activation during AT1 receptor blockade.  
7) The effect of AT1 receptor blockade displays NO sensitivity, whereby NOS inhibition 
eliminated the attenuating effect of AT1 blockade in PE-mediated vasoconstriction 








 To confirm the findings of this study, vasculature serving tissues undergoing less 
metabolic activity during exercise should be studied – for example the mesenteric or renal 
artery.  Increases in ACE activity would be expected in these vessels after exercise and no 
reduction should be observed when PE dose-response curve are completed.  Increases in 
tissue ACE protein have been reported in the kidney following exercise[53].  Our laboratory 
has also determined that ACE activity is increased in the renal artery following exercise. 
 Investigating changes to ACE shedding and secretase activity following exercise 
would provide further insight into the mechanisms by which vascular RAS effects vasomotor 
function.   This study showed that femoral ACE protein and activity decreased following a 
single bout of exercise.  However, the contribution of secretase or shear-induced shedding of 
ACE was not determined.  ACE shedding may be an exciting branch of exercise physiology 
to investigate to fully comprehend the function of vascular RAS during exercise.  In addition, 
the contributions of Ang(1-7) and the bradykinin B2 receptor to vasomotor function 
following exercise should investigated.  An abundance of new research regarding RAS has 
focused on the interesting vasodilatory properties of Ang(1-7)[24;45;48].  Although this 
study did not measure the importance of Ang(1-7), it is possible that it contributed to 
function effects of exercise.  This study recognized that the attenuation of PE responses 
following exercise was NO dependent.  AT2 receptor mediated NO production and reduced 
AT1 receptor activity was partially responsible for the decrease in maximum PE constriction.  
Thus, it is possible that NO production via Ang(1-7) or B2 receptors was participating in the 
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